Last reviewed · How we verify
NCT03094897
Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics
EARLY_PHASE1 trial testing 18F-Al-NOTA-MATBBN PET/CT in Breast Neoplasms in 30 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Wuxi No. 4 People's Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 20 April 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
Drugs / interventions tested
- 18F-Al-NOTA-MATBBN PET/CT — full drug profile →
- PET/CT
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Sponsor
Wuxi No. 4 People's Hospital
Who can join
18 and older, any sex, with Breast Neoplasms or Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective for cancer diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03094897
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Wuxi No. 4 People's Hospital trials
Trials by the same sponsor.
- NCT04989010 — Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors · NA · unknown
- NCT04971369 — Safety Study of 89Zr-NY001 PET Imaging in Patients · NA · unknown
- NCT04977128 — 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors · NA · unknown
- NCT05458089 — 18F-FDG PET/CT in the Diagnosis of Tuberculous Pericarditis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03094897 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wuxi No. 4 People's Hospital
- Last refreshed: 13 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03094897.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing